---
title: "Sutro Biopharma: Buy Rating on Strong ADC Execution, Cash Runway Into 2028, and Multiple 2026 Catalysts"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286599325.md"
description: "Analyst Charles Zhu of LifeSci Capital maintains a Buy rating on Sutro Biopharma with a price target of $54.00, citing strong execution on its ADC pipeline and upcoming catalysts. The lead asset STRO-004 is progressing towards a mid-2026 readout, while additional value is expected from 2026 IND submissions. With a cash position of $203 million extending the runway into 2028, Zhu sees a favorable risk-reward profile for STRO shares. Leerink Partners also assigned a Buy rating with a $43.00 price target."
datetime: "2026-05-15T17:55:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286599325.md)
  - [en](https://longbridge.com/en/news/286599325.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286599325.md)
---

# Sutro Biopharma: Buy Rating on Strong ADC Execution, Cash Runway Into 2028, and Multiple 2026 Catalysts

Analyst Charles Zhu of LifeSci Capital maintained a Buy rating on Sutro Biopharma, with a price target of $54.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Charles Zhu has given his Buy rating due to a combination of factors, including Sutro’s consistent execution on its antibody-drug conjugate pipeline and clear visibility on upcoming catalysts. He underscores the rapid dose escalation progress of lead asset STRO-004, which is advancing toward an initial mid-2026 readout that should validate both the program’s safety profile and the broader platform’s potential.

Zhu also points to additional value from planned 2026 IND submissions for STRO-006 and STRO-227, as well as non-dilutive funding from a recent Astellas collaboration milestone. Combined with a cash position of about $203 million that extends the runway into at least the second quarter of 2028, he views the company as well-capitalized to reach key data events, supporting a favorable risk-reward profile for STRO shares.

Zhu covers the Healthcare sector, focusing on stocks such as IDEAYA Biosciences, Revolution Medicines, and Compass Therapeutics. According to TipRanks, Zhu has an average return of 23.4% and a 56.46% success rate on recommended stocks.

In another report released today, Leerink Partners also assigned a Buy rating to the stock with a $43.00 price target.

### Related Stocks

- [STRO.US](https://longbridge.com/en/quote/STRO.US.md)
- [ALPMY.US](https://longbridge.com/en/quote/ALPMY.US.md)
- [4503.JP](https://longbridge.com/en/quote/4503.JP.md)
- [IDYA.US](https://longbridge.com/en/quote/IDYA.US.md)
- [RVMD.US](https://longbridge.com/en/quote/RVMD.US.md)
- [CMPX.US](https://longbridge.com/en/quote/CMPX.US.md)
- [RVMDW.US](https://longbridge.com/en/quote/RVMDW.US.md)

## Related News & Research

- [Analyst Reiterates Buy on Sutro Biopharma, Citing STRO-004 Phase I Readout and Broader ADC Platform Potential](https://longbridge.com/en/news/286482209.md)
- [Sutro Biopharma Q1 revenue beats analyst expectations](https://longbridge.com/en/news/286462966.md)
- [Top Brass Makes Bold Insider Move at Agree Realty](https://longbridge.com/en/news/286851346.md)
- [Should Agree Realty’s (ADC) Dividend Hike and Insider Buying Shift How Investors View Its Income Strategy?](https://longbridge.com/en/news/287031150.md)
- [Defence Therapeutics Enhances In-House ADC Development Platform with Expanded Analytical and Cellular Testing Capabilities | DTCFF Stock News](https://longbridge.com/en/news/286870222.md)